The state of the art API’s plant, only one of its kind in Takeda group manufactures wide range of products and adhere to stringent regulatory guidelines. The plant complies with the International Conference on Harmonization (ICH) guidelines and Schedule M guidelines in the area of API manufacturing.
Various critical reactions like Oxidation, Chlorination etc. are carried out under strict cGMP & Safety compliance. The plant has implemented energy conservation projects to reduce energy intensity (KWh per unit output) to minimize the carbon footprint. The Company’s core competence in manufacturing is due to its constant efforts to update processes, implement safety measures and focus on consistency in product quality. To meet the increasing demand for APIs in the future, we are multiplying our efforts and gearing up to deliver uncompromising quality in the most cost effective way.
The API’s produced cover a broad range of therapeutic categories listed below.
|Sr. No.||Products||Therapeutic Category|
|4||Lornoxicam||Analgesic / Anti-inflammatory|
|5||Pantoprazole Sodium Sesquihydrate||Anti Ulcerant|
|9||Suxamethonium Chloride Dihydrate||Skeletal Muscle Relaxant|
The API plant has both dedicated and Multiproduct lines with state of the art equipments to minimize exposure of both Product and Personnel